Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EphA3 siRNA
- Development stage
- Preclinical
- Lead developer
- University of Ulsan
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
EphA3 siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of the EphA3 (Ephrin type-A receptor 3) gene. EphA3 is a member of the ephrin receptor subfamily of protein-tyrosine kinases and is involved in various oncogenic processes, including cell-cell adhesion, invasion, neo-angiogenesis, and metastasis. Research indicates that EphA3 is overexpressed in radioresistant head and neck cancer cell lines and clinical specimens. By inhibiting EphA3, the siRNA suppresses the epithelial-mesenchymal transition (EMT) pathway, thereby reducing tumor invasiveness and migration while significantly enhancing the sensitivity of cancer cells to radiotherapy. This suggests that EphA3 siRNA could serve as a potent radiosensitizer in the treatment of head and neck squamous cell carcinomas.
- Other names
- EphA3 small interfering RNAEphA-3 small interfering RNAEphA 3 small interfering RNA
02
Targets
EPHA3 (Ephrin Receptor A3)
Beyond the preview
Go deeper on EphA3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EphA3 siRNA.